ABVC BIOPHARMA, INC. (ABVC) SEC Filings

ABVC BioPharma, Inc. (ABVC) is calling a virtual special shareholders’ meeting on September 18, 2026 to vote on three proposals. Shareholders of record on July 24, 2026, when 26,554,365 common shares were outstanding, are entitled to one vote per share. Voting is by proxy only; no votes will be taken live at the Zoom meeting.

Proposal 1 seeks approval of a new 2026 Equity Incentive Plan, replacing the terminated 2016 plan. The new plan’s initial Award Pool equals 1,169,201 shares plus 15% of common shares outstanding on the meeting date, with an annual automatic increase of 5% of outstanding shares beginning January 1, 2027. For illustration, if the meeting were held as of the record date, the Award Pool would be 5,152,356 shares.

Proposal 2 asks shareholders to ratify 600,000 shares of common stock granted to two advisors (50,000 shares per advisor per month for six months) after the 2016 plan’s February 16, 2026 termination, which would become governed by the 2026 plan if approved. Proposal 3 requests authorization under Nasdaq Listing Rule 5635(d) for potential issuance of up to 6,638,591 shares of common stock (or equivalent securities) at a price not less than $1.00 per share as part or all of the consideration for acquiring specified land and real property in Taoyuan and Hualien, Taiwan, from director Shuling Jiang, a related-party transaction. The properties have an aggregate appraised value of NT$20,095,008 (approximately US$622,291 at NT$32.292/US$1.00). The Board unanimously recommends voting FOR all three proposals.

ABVC BioPharma, Inc. filed a prospectus supplement registering 3,400,187 shares of common stock issuable upon exercise of a common stock purchase warrant, updating its August 7, 2024 prospectus. As of August 10, 2026, ABVC had 26,654,365 common shares outstanding.

For the six months ended June 30, 2026, ABVC generated no revenue and recorded a net loss of $2,500,418, compared with a $3,277,023 loss a year earlier. Cash and cash equivalents were $31,944 versus $681,480 at December 31, 2025, contributing to a working capital deficit of $5,282,776 and operating cash outflows of $1,138,656. The company reports that these conditions raise substantial doubt about its ability to continue as a going concern and plans to rely on improved operations, capital raising and related-party support.

ABVC also describes a planned partial separation of its BioKey Cayman business. It intends to distribute approximately 4,500,000 BioKey Cayman ordinary shares, representing about 15% of BioKey Cayman, pro rata to ABVC shareholders, while retaining roughly 85%. The distribution, originally targeted for August 3, 2026, has been postponed pending tax, administrative and regulatory matters, and no revised date has been set.

ABVC BioPharma, Inc. filed a prospectus supplement covering 225,500 shares of common stock under its existing May 22, 2024 prospectus, while incorporating its Quarterly Report for the period ended June 30, 2026.

For the first six months of 2026, ABVC generated no revenue and recorded a net loss of $2,500,418 and a comprehensive loss of $2,286,585. Cash and cash equivalents declined to $31,944 from $681,480 at year-end 2025, with net cash used in operating activities of $1,138,656. Total assets were $19,400,715 and total liabilities $7,131,155, resulting in total equity of $12,269,560.

The company discloses a working capital deficit of $5,282,776 and states that these conditions, along with continued operating losses and cash outflows, raise substantial doubt about its ability to continue as a going concern. Management plans to seek additional capital through private or public offerings and related-party or shareholder support, and to improve operations to generate positive cash flows. As of August 10, 2026, ABVC had 26,654,365 common shares outstanding.

ABVC BioPharma, Inc. filed a prospectus supplement updating its shelf registration covering 11,714,683 shares of common stock and incorporating its Quarterly Report for the period ended June 30, 2026. The company remains a pre‑revenue biotech focused on plant‑derived drugs and medical devices.

For the six months ended June 30, 2026, ABVC reported a net loss of $2,500,418 and used $1,138,656 in operating cash. Cash and cash equivalents declined to $31,944, and the company had a working capital deficit of $5,282,776, leading management to state that these conditions raise substantial doubt about its ability to continue as a going concern.

Total assets were $19.4 million, including $12.8 million of property and equipment and $2.5 million of long‑term investments. ABVC is also pursuing a partial spin‑off of its BioKey Cayman business, planning to distribute about 15% of BioKey Cayman shares to ABVC shareholders once tax and regulatory issues are resolved.

ABVC BioPharma, Inc. is using this prospectus supplement to register 1,000,000 shares of common stock issuable upon exercise of a common stock purchase warrant, and to incorporate its latest Quarterly Report for the period ended June 30, 2026.

The company reported no revenue, a six‑month net loss of $2.50 million, and operating cash outflows of $1.14 million. Cash and cash equivalents fell to $31,944, with a working capital deficit of $5.28 million, leading management to state that these conditions raise substantial doubt about its ability to continue as a going concern. Total assets were $19.4 million and total liabilities $7.13 million.

ABVC is progressing a planned separation of its BioKey Cayman business, with BioKey Cayman already an Exchange Act reporting company and ABVC intending to distribute about 4,500,000 BioKey Cayman shares (approximately 15% of BioKey Cayman) to ABVC shareholders on a pro rata basis, though the distribution has been postponed.

ABVC BioPharma, Inc. is calling a virtual special shareholders’ meeting on September 18, 2026 to vote on three governance and capital-structure items. Shareholders of record on July 24, 2026, when 26,554,365 common shares were outstanding, are entitled to one vote per share.

The first proposal seeks approval of a new 2026 Equity Incentive Plan, replacing the expired 2016 plan. The new plan’s share Award Pool will include 1,169,201 remaining shares from the prior plan plus 15% of shares outstanding on the meeting date, and will increase annually by 5% of shares outstanding as of each prior December 31.

The second proposal asks shareholders to ratify 600,000 shares of common stock granted as equity awards to two advisors after the 2016 plan’s termination, which would then be governed by the 2026 plan. The third proposal seeks authorization, under Nasdaq Listing Rule 5635(d), to issue up to 6,638,591 shares of common stock (or equivalent securities) at a price not less than $1.00 per share as consideration for acquiring specified properties in Taoyuan and Hualien, Taiwan. These properties are currently owned by director Shuling Jiang, making this a related-party transaction. The Board unanimously recommends voting FOR all three proposals.

ABVC BioPharma, Inc. reported no revenues for the three and six months ended June 30, 2026, and continued to incur losses. Net loss was $810,481 for the quarter and $2,500,418 for the first half of 2026, with basic and diluted loss per share of $0.03 and $0.09, respectively.

Total assets were $19.4 million as of June 30, 2026, down from $21.1 million at December 31, 2025, while total liabilities were $7.1 million, resulting in total equity of $12.3 million. Cash and cash equivalents declined sharply to $31,944, and the company disclosed a working capital deficit of $5,282,776.

Operating activities used $1,138,656 of cash in the first half of 2026, and management stated that recurring losses, negative operating cash flows, limited cash, and the working capital deficit raise substantial doubt about the company’s ability to continue as a going concern absent improved operations and additional financing.

ABVC BioPharma, Inc. postponed the previously announced distribution of ordinary shares of BioKey (Cayman), Inc. that had been scheduled for August 3, 2026. The company now expects the distribution to occur on August 21, 2026, after completing additional administrative, regulatory and tax-related steps.

The record date remains July 24, 2026, and shareholders of ABVC common stock as of that date are expected to receive 0.169464 ordinary shares of BioKey for each ABVC share. The earlier ex-dividend date will be replaced, and a new ex-dividend date will be announced once finalized.

ABVC BioPharma, Inc. has postponed the previously announced distribution of ordinary shares of BioKey (Cayman), Inc., which had been scheduled to occur on August 3, 2026. The decision on August 3, 2026 allows additional time to complete administrative, regulatory, and tax-related requirements needed to carry out the distribution.

The record date for the distribution remains unchanged, and the distribution ratio is unchanged at 0.169464 BioKey ordinary shares for each share of ABVC common stock held as of that record date. The prior ex-dividend date will no longer apply and will be reset when a new distribution date is established. ABVC is working with Nasdaq, The Depository Trust Company, and its transfer agent and plans to announce the revised distribution and ex-dividend dates once finalized.